GU Cancers 2024 | The future of genetic testing and targeted therapies in prostate cancer

Channing Paller, MD, The Johns Hopkins University, Baltimore, MD, comments on what the future holds for genetic testing in patients with prostate cancer. Initiatives such as the PROMISE registry, which aims to record the frequency of various genetic mutations in prostate cancer, will hopefully enhance testing rates. Dr Paller also highlights the need for more prevalent genetic testing to advance the field of precision medicine. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.